Nuance Investments LLC Takes $11.58 Million Position in Kenvue Inc. $KVUE

Nuance Investments LLC acquired a new position in Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 713,402 shares of the company’s stock, valued at approximately $11,579,000. Kenvue comprises approximately 1.2% of Nuance Investments LLC’s holdings, making the stock its 25th largest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. Cornerstone Planning Group LLC increased its stake in shares of Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY lifted its stake in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after purchasing an additional 1,006 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in Kenvue in the third quarter worth $25,000. Golden State Wealth Management LLC increased its position in Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont increased its position in Kenvue by 50.9% during the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the purchase, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.17% of the company’s stock.

Kenvue Stock Performance

KVUE opened at $18.12 on Monday. The firm has a market capitalization of $34.72 billion, a P/E ratio of 24.16 and a beta of 0.59. The stock’s 50 day moving average price is $17.24 and its two-hundred day moving average price is $17.83. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is presently 110.67%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $15.00 price target (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a research report on Friday, October 24th. Four investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.46.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.